Amylyx price target raised to $25 from $17 at Guggenheim

Guggenheim analyst Seamus Fernandez raised the firm’s price target on Amylyx (AMLX) to $25 from $17 and keeps a Buy rating on the shares. Continued diligence on the post-bariatric hypoglycemia market opportunity and recent comps analysis increases the firm’s conviction that Amylyx is “uniquely positioned to deliver on the PBH market’s blockbuster potential and become the next big player in rare metabolic disorders,” the analyst tells investors.